Orakl Oncology

Orakl Oncology is a techbio platform connecting new assets to target cancer patients to ensure successful market access. Orakl Oncology first-in-class clinical trial predictor integrates functional testing in the wetlab and AI-powered analyses to predict patient responses in the clinic. Through this, for our partners and our internal pipeline, we: – Match new assets with responding patients to ensure clinical trial success – Inform strategic decisions based on objective data to ensure efficient market access – Identify additional segments of responding patients for market extension We leverage a unique collection of patient tumor avatars, and one of the largest. Each avatar combines the best biology and deep longitudinal clinical and molecular data, starting from pancreatic and colorectal cancers. The start-up is a spin-out from Gustave Roussy. With over 30 years of combined scientific experience across France, the UK, and the US, the team is dedicated to improving cancer research. For more information, please visit www.orakl-oncology.com